Summary
- Profile Type
- Technology request
- POD Reference
- TRFR20250516020
- Term of Validity
- 16 May 2025 - 16 May 2026
- Company's Country
- France
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
The company is developing a drug to treat traumatic brain injury using a molecule extracted from marine macroalgae. This molecule targets the immune system to promote repair after brain trauma. The therapy aims to reduce stimulate the immune cells and enhance neurological recovery.
We also work to valorise extraction by-products, ensuring a sustainable, biotech-driven approach to neurorepair.
Expertise is sought in polysaccharide chemistry and extraction of molecules at pharmaceutical grade - Full Description
-
We are a biotechnology company focused on developing innovative therapies derived from marine algae. Our lead program targets the treatment of traumatic brain injury (TBI), a major public health concern (50m people/year) with limited therapeutic options.
Our company has identified and isolated a unique bioactive molecule, a polysaccharide, from marine macroalgae with potent immunomodulatory properties. This molecule is capable of reprogramming the immune response following a traumatic brain injury, reducing harmful neuroinflammation and promoting neural repair mechanisms.
TBI often triggers a cascade leading to immune deficiency that exacerbate damage to brain tissue. Our approach is to modulate this response at a critical window post-injury, aiming to limit secondary damage and support regeneration. Preclinical studies have shown that the compound improves immune status, clinical score and skull and brain regeneration in TBI models, while demonstrating a good safety profile.
In parallel, we are committed to sustainable innovation. The company is developing methods to valorise the co-products of the macroalgae extraction process, converting what would otherwise be waste into valuable ingredients for the cosmetic, nutraceutical and other sectors.
With its multidisciplinary expertise in marine biology, immunology, and drug development, our company is positioning itself as a pioneer in marine-based therapeutics for central nervous system injuries. The company’s drug candidate holds promise not only for TBI patients but also for broader applications in neuroinflammatory and neurodegenerative disorders. - Advantages and Innovations
-
*** First-in-class marine-derived drug for TBI ***
The molecule developed by our company is sourced from marine macroalgae, a completely novel origin for neurotherapeutics and no current treatment exists that directly modulates the immune response to promote repair after traumatic brain injury with such biological properties. There is also a strong Immuno-modulation and rather than suppressing inflammation globally (which can hinder healing), our compound reprograms the immune system to reduce harmful effects while en-hancing repair an original and unique approach to TBI.
We have a strong preclinical efficacy as the compound shows significant improvement in cognitive and motor functions in animal models.
**Valorization of by-products for cosmetics and nutraceutical ***
In addition we have a sustainable bioproduction. Indeed the drug is derived from renewable marine biomass, avoiding synthetic or animal-based sourcing. Our company uses a circular bioeconomy model, valorizing co-products from extraction for other industries (cosmetics, nutraceutical), which reduces waste and adds revenue streams. Last, we have a Broad therapeutic potential, While initially developed for TBI, the mechanism of action could be relevant for other neuroinflammatory or neurodegenerative condi-tions, such as multiple sclerosis or Alzheimer’s disease, opening doors for future pipeline expansion. - Technical Specification or Expertise Sought
-
We are looking for the following expertise :
- Polysaccharide chemistry (de novo synthesis / hemi synthesis)
- Extraction of molecule at pharmaceutical grade
- Cosmetics / nutraceutical industry knowledge and commercial skills - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
- some IPR is already granted
Partner Sought
- Expected Role of a Partner
-
*** We are actively seeking an R&D partner to accelerate the development of its marine-derived therapeutic for traumatic brain injury (TBI) ***
The ideal partner will bring complementary expertise and capabilities to strengthen the preclinical and translational development phases, and potentially co-develop the clinical program.
The expected role of the partner includes:
• Advanced pharmacology and mechanism of action studies, helping to further characterize the bioactive compound’s effects on neuroinflammation and immune pathways.
• In vivo efficacy testing in additional TBI models, including complex or chronic injury models to expand therapeutic indications and validate long-term benefits.
• Formulation development and optimization, particularly for i.v delivery
• Regulatory expertise to assist in the design and submission of pre-IND or clinical trial documentation.
Our company also welcomes collaboration on biomarker discovery, companion diagnostics, and exploration of the compound's broader neuroprotective potential in related conditions such as stroke or neurodegenerative diseases.
The collaboration can be structured through co-development agreements, licensing partner-ships, or public-private consortia, depending on the partner’s profile. The ideal partner will share our vision of sustainable biotech innovation and marine-based solutions for unmet medical needs. - Type and Size of Partner
- SME <=10
- SME 11-49
- SME 50 - 249
- R&D Institution
- Big company
- University
- Type of partnership
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001015 - Pharmaceutical Products / Drugs
- Market keywords
- 05005013 - Emergency medicine
- 05005022 - Other clinical medicine
- 05007002 - Pharmaceuticals/fine chemicals
- Sector Groups Involved
- Health
- Targeted countries
- All countries